Researcher Andrew Dai believes that the artificial intelligence models at big labs have the intelligence of a 3-year-old kid, at least when it comes to making sense of visual prompts.

One year-old Aria Networks of Palo Alto has raised $125 million and has announced general availability of its AI-native ...

High-speed rail connecting Toronto and Quebec City would be a boon to the economy and job creation, Prime Minister Mark ...

H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience. ・Baird cut Alto’s price target to $38 from $41 but said the company’s ...

Alto Neuroscience deprioritized its lead asset Thursday, a treatment for cognitive impairment due to schizophrenia. The ...

Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell ...

Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...

Alto Neuroscience missed the primary endpoint for a study of its ALTO-101 drug for the treatment of cognitive impairment associated with schizophrenia.

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 ...

Alto’s ALTO-207 program remains on track to initiate a Phase 2b trial in the first half of 2026. The planned trial will evaluate ALTO-207 as an adjunctive treatment in approximately 178 adults with ...

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that ...

Strong improvement in fiscal performance has sent Alto Ingredients up 180% over the past year. Continued capacity expansion is well-cited as a possible catalyst for shares, but another catalyst ...